» Articles » PMID: 1322013

Effects of Growth Factors on Corneal Wound Healing

Overview
Specialty Ophthalmology
Date 1992 Jan 1
PMID 1322013
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Healing of ocular surface wounds is a complex process involving migration, mitosis, and differentiation of epithelial and stromal cells. Endogenously produced peptide growth factors such as epidermal growth factor (EGF), transforming growth factor alpha (TGF-alpha), or transforming growth factor beta (TGF-beta) may play key roles in the natural wound healing process. Lacrimal gland cells were reported to synthesize and secrete EGF into tear fluid where it may enhance healing of corneal epithelial and stromal injuries by an exocrine pathway. EGF stimulated DNA synthesis of epithelial cells and stromal fibroblasts in culture, stimulated synthesis of fibronectin by epithelial cells and was chemotactic for human epithelial and stromal cells. Human corneal epithelial cells also synthesized TGF-alpha which may influence epithelial cells by an autocrine pathway. TGF-beta, which is a potent inducer of lysyl oxidase mRNA levels in cultures of human scleral fibroblasts, may be the factor most responsible for inducing synthesis of corneal extracellular matrix components after an injury. Treatment of epithelial injuries ocular surface wounds with exogenous peptide growth factors also accelerated healing in rabbits and primates. Treatment of severe ocular surface injuries caused by alkali with a combination of EGF, fibronectin, a synthetic collagenase inhibitor, and Aprotinin significantly blocked ulceration and enhanced epithelial regeneration. Clinical trials of topical treatment of EGF for ocular surface wounds suggest that peptide growth factors may be a valuable adjuvant for treatment of ocular surface wounds.

Citing Articles

Clinically correlated dose of the amniotic membrane extract is superior to its transplantation in corneal wound healing.

Korkmaz I, Kocamanoglu M, Gurdal M, Arici M, Yaman B, Palamar M Mol Vis. 2024; 30:188-199.

PMID: 39563677 PMC: 11575842.


Medrysone promotes corneal injury repair by promoting M2-like polarization of macrophages.

Zhu Y, Jin X, Fu N, Li J BMC Ophthalmol. 2023; 23(1):503.

PMID: 38082280 PMC: 10712160. DOI: 10.1186/s12886-023-03234-3.


Comparison of epitheliotrophic factors in platelet-rich plasma versus autologous serum and their treatment efficacy in dry eye disease.

Metheetrairut C, Ngowyutagon P, Tunganuntarat A, Khowawisetsut L, Kittisares K, Prabhasawat P Sci Rep. 2022; 12(1):8906.

PMID: 35618742 PMC: 9135723. DOI: 10.1038/s41598-022-12879-x.


Topical Umbilical Cord Serum for Corneal Epithelial Defects after Diabetic Vitrectomy.

Moradian S, Ebrahimi M, Kanaani A, Faramarzi A, Safi S J Ophthalmic Vis Res. 2020; 15(2):160-165.

PMID: 32308949 PMC: 7151505. DOI: 10.18502/jovr.v15i2.6732.


Persistent Corneal Epithelial Defects: A Review Article.

Vaidyanathan U, Hopping G, Liu H, Somani A, Ronquillo Y, Hoopes P Med Hypothesis Discov Innov Ophthalmol. 2019; 8(3):163-176.

PMID: 31598519 PMC: 6778469.